Department of Orthopaedic Surgery, Center for Joint Diseases, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.
Department of Orthopaedic Surgery, School of Medicine, Kyung Hee University, Seoul, Republic of Korea.
Stem Cells Transl Med. 2022 Jun 22;11(6):572-585. doi: 10.1093/stcltm/szac023.
Intra-articular injection of adipose-derived mesenchymal stem cell (ADMSC) after medial open-wedge high tibial osteotomy (MOWHTO) would be a promising disease-modifying treatment by correcting biomechanical and biochemical environment for arthritic knee with varus malalignment. However, there is a paucity of clinical evidence of the treatment. This randomized controlled trial (RCT) was aimed to assess regeneration of cartilage defect, functional improvement, and safety of intra-articular injection of ADMSCs after MOWHTO compared with MOWHTO alone for osteoarthritic knee with varus malalignment. This RCT allocated 26 patients into the MOWHTO with ADMSC-injection group (n = 13) and control (MOWHTO-alone) group (n = 13). The primary outcome was the serial changes of cartilage defect on periodic magnetic resonance imaging (MRI) evaluation using valid measurements until postoperative 24 months. Secondary outcomes were the 2-stage arthroscopic evaluation for macroscopic cartilage status and the postoperative functional improvements of patient-reported outcome measures until the latest follow-up. Furthermore, safety profiles after the treatment were evaluated. Cartilage regeneration on serial MRIs showed significantly better in the ADMSC group than in the control group. The arthroscopic assessment revealed that total cartilage regeneration was significantly better in the ADMSC group. Although it was not significant, functional improvements after the treatment showed a tendency to be greater in the ADMSC group than in the control group from 18 months after the treatment. No treatment-related adverse events, serious adverse events, and postoperative complications occurred in all cases. Concomitant intra-articular injection of ADMSCs with MOWHTO had advantages over MOWHTO alone in terms of cartilage regeneration with safety at 2-year follow-up, suggesting potential disease-modifying treatment for knee OA with varus malalignment.
关节内注射脂肪间充质干细胞(ADMSC)治疗内侧开放楔形胫骨高位截骨术(MOWHTO)后,可通过纠正内翻畸形关节炎膝的生物力学和生化环境,成为一种有前途的疾病修正治疗方法。然而,这种治疗方法的临床证据很少。这项随机对照试验(RCT)旨在评估与单独 MOWHTO 相比,MOWHTO 后关节内注射 ADMSCs 对内侧畸形的骨关节炎膝的软骨缺损再生、功能改善和安全性。这项 RCT 将 26 例患者分为 MOWHTO 联合 ADMSC 注射组(n = 13)和对照组(单独 MOWHTO 组,n = 13)。主要结局是使用有效测量方法在术后 24 个月内定期磁共振成像(MRI)评估软骨缺损的连续变化。次要结局是 2 期关节镜评估宏观软骨状况和患者报告的结果测量术后功能改善,直到最新随访。此外,还评估了治疗后的安全性概况。MRI 上的软骨再生在 ADMSC 组明显优于对照组。关节镜评估显示,ADMSC 组的总软骨再生明显更好。尽管没有统计学意义,但从治疗后 18 个月开始,ADMSC 组的治疗后功能改善趋势大于对照组。所有病例均无治疗相关不良事件、严重不良事件和术后并发症。MOWHTO 联合关节内注射 ADMSCs 在安全性方面优于单独 MOWHTO,在 2 年随访时具有软骨再生优势,提示其可能成为内翻畸形膝骨关节炎的一种潜在的疾病修正治疗方法。